Dara BioSciences

Pharma

DARA securities sale nets $9.2M; proceeds to support cancer portfolio

The cancer products portfolio that DARA BioSciences (NASDAQ:DARA) has been building by acquisition now has more than $9 million in fresh capital to help bring those products to market. The pharmaceutical company has completed a securities offering of preferred stock and warrants, according to securities filings. Raleigh, North Carolina-based DARA sold 10,250 shares of preferred […]

Pharma

Generic cancer treatment added to DARA portfolio in Uman Pharma deal

The cancer treatment portfolio of DARA BioSciences (NASDAQ:DARA) is getting bigger as the pharmaceutical company strikes a deal to market the generic version of a drug used as a first-in-line treatment for several cancers. DARA’s deal with Canadian specialty pharmaceutical company Uman Pharma gives DARA exclusive rights to commercialize gemcitabine in the United States. But […]

Pharma

Private placement will yield DARA BioSciences $1.7M

DARA BioSciences (NASDAQ:DARA), which earlier this week acquired cancer therapeutics firm Oncogenerix, has made yet another deal, this one an agreement to raise $1.7 million in a private placement. DARA has reached a definitive agreement with an unnamed institutional investor to sell preferred stock valued at $1.7 million and warrants to purchase 619,308 shares of […]

Pharma

DARA BioSciences CEO Franco to retire

DARA BioSciences (NASDAQ:DARA) is looking for a new CEO. Current CEO Richard Franco will retire from his posts as chairman, president and CEO of the Raleigh, North Carolina biotechnology company effective Dec. 16. DARA said that Dr. David Drutz, a member of the company’s board of directors, will serve as interim CEO. Franco notified the […]

Pharma

DARA falls short of NASDAQ requirement, could lose listing

Drug development company DARA BioSciences (NASDAQ:DARA) could lose its listing on the NASDAQ exchange today. DARA received notification from the NASDAQ that based on its last quarterly report, the Raleigh, North Carolina company no longer maintained the minimum $2.5 million in stockholders’ equity required for a listing. DARA said in a securities filing that the […]

Pharma

DARA BioSciences gets five more patents for pain, diabetes portfolio

North Carolina biotechnology company DARA BioSciences (NASDAQ:DARA) has strengthened its intellectual position by securing five new patents for its drug pipeline. DARA said the five new patents were granted in the United States, Asia and Israel. The Raleigh, North Carolina company has two drug candidates in clinical trials. KRN5500 is in development as a treatment […]

Pharma

Nerve pain compound for cancer patients gets FDA fast-track for DARA

DARA BioSciences‘s (NASDAQ:DARA) investigational pain treatment for cancer patients now has fast-track status from the U.S. Food and Drug Administration. The compound KRN5500 is being developed with the National Cancer Institute to treat neuropathic pain brought on by chemotherapy. The FDA’s fast-track program is intended to facilitate development and speed regulatory review of new drugs […]

Pharma

DARA BioSciences awarded patents for its pain, diabetes drug pipeline

Intellectual property protection for DARA BioSciences‘s drug pipeline just got a little more secure. Raleigh, North Carolina-based DARA (NASDAQ:DARA) has been issued nine patents in the United States and around the world, which gives it additional intellectual property protection for compounds being developed as new treatments for diabetes, obesity, cardiovascular disease and pain. DARA does […]

Pharma

N.C. pharma DARA BioSciences updates $30M stock filing

Drug development company DARA BioSciences is updating its plans to raise up to $30 million through a stock sale. Raleigh, North Carolina-based DARA (NASDAQ:DARA) has filed a new shelf registration statement with the U.S. Securities and Exchange Commission, which replaces a filing set to expire on April 18. DARA said it has no plans to […]